Inhibikase Therapeutics, Inc. 8K

Inhibikase Therapeutics furnished an investor presentation outlining the development, Phase 3 program, and strategic positioning of its PAH drug candidate IKT-001.

Inhibikase Therapeutics, Inc. furnished a corporate overview presentation as an Exhibit 99.1 to its Form 8-K, describing its lead candidate IKT-001, a novel oral prodrug of imatinib in a global, pivotal Phase 3 IMPROVE-PAH trial for pulmonary arterial hypertension, highlighting its clinical rationale, trial design, regulatory status including orphan drug designation and a 505(b)(2) pathway, projected development timelines through 2029, and an asserted cash runway through the Part B topline data readout, while including standard forward-looking statement and risk disclosures.

Filing Facts

CIK

1750149

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-385293

Alert Tier

5